FNAM (Evolutionary Genomics) NonCurrent Deferred Revenue: $0.00 Mil (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FNAM Evolutionary Genomics Inc FNAM
31 GF Score
Price $0.00
View Full Analysis

What is Evolutionary Genomics NonCurrent Deferred Revenue?

Evolutionary Genomics FNAM 31 NonCurrent Deferred Revenue is $0.00 Mil as of Dec. 2022. GuruFocus rates FNAM with a GF Score™ of 31/100.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Evolutionary Genomics's non-current deferred revenue for the quarter that ended in Dec. 2022 was $0.00 Mil.

Evolutionary Genomics NonCurrent Deferred Revenue Related Terms

Evolutionary Genomics NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Evolutionary Genomics's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolutionary Genomics NonCurrent Deferred Revenue Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FNAM
31GF Score
Evolutionary Genomics Inc FNAM
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0.00 Mil mean?
Evolutionary Genomics (FNAM) has a NonCurrent Deferred Revenue of $0.00 Mil as of Dec. 2022. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Evolutionary Genomics and its competitors.
Is Evolutionary Genomics' NonCurrent Deferred Revenue too high?
Evolutionary Genomics' current NonCurrent Deferred Revenue is $0.00 Mil. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Evolutionary Genomics' NonCurrent Deferred Revenue compare to BXRX and GNCA?
Evolutionary Genomics' NonCurrent Deferred Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Biotechnology company?
A good NonCurrent Deferred Revenue depends on the Biotechnology industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Evolutionary Genomics and its competitors. Evolutionary Genomics's current NonCurrent Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolutionary Genomics stock overvalued right now?
Evolutionary Genomics (FNAM) has a current NonCurrent Deferred Revenue of $0.00 Mil. The current NonCurrent Deferred Revenue is $0.00 Mil. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current NonCurrent Deferred Revenue is $0.00 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evolutionary Genomics Business Description

Address 4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
31GF Score

Get the complete analysis for FNAM

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price